IceCure Medical Ltd (ICCM)
NASDAQ: ICCM · Real-Time Price · USD
3.650
-0.010 (-0.27%)
At close: Jul 17, 2026, 4:00 PM EDT
3.640
-0.010 (-0.27%)
After-hours: Jul 17, 2026, 7:57 PM EDT
IceCure Medical Revenue
IceCure Medical had revenue of $911.00K in the quarter ending March 31, 2026, with 25.66% growth. This brings the company's revenue in the last twelve months to $3.57M, up 8.92% year-over-year. In the year 2025, IceCure Medical had annual revenue of $3.38M with 2.67% growth.
Revenue (ttm)
$3.57M
Revenue Growth
+8.92%
P/S Ratio
3.51
Revenue / Employee
$51,667
Employees
69
Market Cap
12.51M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.38M | 88.00K | 2.67% |
| Dec 31, 2024 | 3.29M | 62.00K | 1.92% |
| Dec 31, 2023 | 3.23M | 144.00K | 4.67% |
| Dec 31, 2022 | 3.09M | -1.05M | -25.45% |
| Dec 31, 2021 | 4.14M | 270.00K | 6.98% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| IRIDEX | 52.58M |
| Trinity Biotech | 43.79M |
| Lifeward | 20.92M |
| NeuroOne Medical Technologies | 12.72M |
| Picard Medical | 5.47M |
| VolitionRx | 2.47M |
| Co-Diagnostics | 718.17K |
| Nexalin Technology | 275.58K |
ICCM News
- 4 days ago - IceCure Medical expands U.S. commercial team for ProSense cryoablation - TheFly
- 4 days ago - IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® Cryoablation - PRNewsWire
- 4 days ago - IceCure Medical Slides: Investor presentation - Filings
- 12 days ago - IceCure Medical highlights expanding commercial adoption of ProSense - TheFly
- 12 days ago - IceCure Highlights Expanding Commercial Adoption of ProSense™ Cryoablation in Brazil Following FDA Clearance for Breast Cancer - PRNewsWire
- 23 days ago - IceCure Medical registers to sell 5.5M ordinary shares for holders - TheFly
- 23 days ago - IceCure Medical regains compliance with Nasdaq minimum bid price requirement - TheFly
- 23 days ago - IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement - PRNewsWire